Cargando…

Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: An analysis of the MASTERPLAN cohort

BACKGROUND: Fibroblast growth factor 23 (FGF23) has emerged as a risk factor for cardiovascular disease and mortality throughout all stages of chronic kidney disease (CKD), independent from established risk factors and markers of mineral homeostasis. The relation of FGF23 with other renal and non-re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vervloet, Marc G, van Zuilen, Arjan D, Heijboer, Annemieke C, ter Wee, Piet M, Bots, Michiel L, Blankestijn, Peter J, Wetzels, Jack FM
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366907/ https://www.ncbi.nlm.nih.gov/pubmed/22530966 http://dx.doi.org/10.1186/1471-2369-13-20

Ejemplares similares

Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. Design of The MASTERPLAN Study [ISRCTN73187232]
por: van Zuilen, Arjan D, et al.
Publicado: (2006)

Abdominal aortic calcification in patients with CKD
por: Peeters, Mieke J., et al.
Publicado: (2016)

Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients
por: Bech, Anneke P., et al.
Publicado: (2015)

The urban masterplanning handbook
por: Firley, Eric
Publicado: (2013)

Differences between hospitals in attainment of parathyroid hormone treatment targets in chronic kidney disease do not reflect differences in quality of care
por: Peeters, Mieke J, et al.
Publicado: (2012)

CERN Masterplan: stratégie générale
por: CERN
Publicado: (2015)

The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations
por: Heijboer, Annemieke C., et al.
Publicado: (2022)

CERN Masterplan 2040: stratégie générale
por: Poehler, Michael
Publicado: (2021)

CERN Masterplan 2040: General strategy
por: Poehler, Michael
Publicado: (2021)

Masterplan Rohstoffe 2030 – Eine Rohstoffstrategie für Österreich
por: Reichhardt, Andreas, et al.
Publicado: (2022)

Reduction of Oxidative Stress in Chronic Kidney Disease Does Not Increase Circulating α-Klotho Concentrations
por: Adema, Aaltje Y., et al.
Publicado: (2016)

Short-term effects of sevelamer-carbonate on fibroblast growth factor 23 and pulse wave velocity in patients with normophosphataemic chronic kidney disease Stage 3
por: Bouma-de Krijger, Annet, et al.
Publicado: (2019)

Influence of exogenous growth hormone administration on circulating concentrations of α-klotho in healthy and chronic kidney disease subjects: a prospective, single-center open case-control pilot study
por: Adema, Aaltje Y., et al.
Publicado: (2018)

Commissioning of brachytherapy module of Oncentra MasterPlan treatment planning system
por: de Oliveira, Carla Alves, et al.
Publicado: (2010)

High Fibroblast Growth Factor 23 concentrations in experimental renal failure impair calcium handling in cardiomyocytes
por: Verkaik, Melissa, et al.
Publicado: (2018)

Uremic Solutes in Chronic Kidney Disease and Their Role in Progression
por: van den Brand, Jan A. J. G., et al.
Publicado: (2016)

Localization of fibroblast growth factor 23 protein in the rat hypothalamus
por: Ursem, Stan R., et al.
Publicado: (2021)

Verification of Varian enhanced dynamic wedge implementation in MasterPlan treatment planning system
por: Pasquino, Massimo, et al.
Publicado: (2009)

Living in an Age-Friendly Community: Evidence from a Masterplanned Development in Southwest Sydney
por: Jones, Alasdair, et al.
Publicado: (2023)

Hepcidin-25 in Chronic Hemodialysis Patients Is Related to Residual Kidney Function and Not to Treatment with Erythropoiesis Stimulating Agents
por: van der Weerd, Neelke C., et al.
Publicado: (2012)

Fibroblast growth factor 23: are we ready to use it in clinical practice?
por: Bouma-de Krijger, Annet, et al.
Publicado: (2020)

Stereotactic radiotherapy of intrapulmonary lesions: comparison of different dose calculation algorithms for Oncentra MasterPlan®
por: Troeller, Almut, et al.
Publicado: (2015)

Effect of increased convective clearance by on-line hemodiafiltration on all cause and cardiovascular mortality in chronic hemodialysis patients – the Dutch CONvective TRAnsport STudy (CONTRAST): rationale and design of a randomised controlled trial [ISRCTN38365125]
por: Penne, E Lars, et al.
Publicado: (2005)

Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy
por: Humalda, Jelmer K., et al.
Publicado: (2016)

Serum Magnesium and Sudden Death in European Hemodialysis Patients
por: de Roij van Zuijdewijn, Camiel L. M., et al.
Publicado: (2015)

Evaluation of volumetric modulated arc therapy (VMAT) with Oncentra MasterPlan(® )for the treatment of head and neck cancer
por: Alvarez-Moret, Judith, et al.
Publicado: (2010)

Strategic Database Marketing 4e: The Masterplan for Starting and Managing a Profitable, Customer-Based Marketing Program
por: Hughes, Arthur
Publicado: (2011)

Position of the advisory and executive board of the German Association for Medical Education (GMA) regarding the “masterplan for medical studies 2020”
Publicado: (2019)

COVID-19 vaccination and Atypical hemolytic uremic syndrome
por: Bouwmeester, Romy N., et al.
Publicado: (2022)

Low plasma magnesium concentration and future abdominal aortic calcifications in moderate chronic kidney disease
por: ter Braake, Anique D., et al.
Publicado: (2021)

Reference values of renal tubular function tests are dependent on age and kidney function
por: Bech, Anneke P., et al.
Publicado: (2017)

The effect of natriuretic C-type peptide and its change over time on mortality in patients on haemodialysis or haemodiafiltration
por: de Roij van Zuijdewijn, Camiel L M, et al.
Publicado: (2019)

Clinical evidence on haemodiafiltration
por: Blankestijn, Peter J, et al.
Publicado: (2018)

Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis
por: Wolf, Myles, et al.
Publicado: (2019)

Shedding Light on the Complex Regulation of FGF23
por: Vervloet, Marc G.
Publicado: (2022)

Terahertz spectra of proteinuria and non-proteinuria
por: Xue, Zhenrui, et al.
Publicado: (2023)

Should We Still Focus That Much on Cardiovascular Mortality in End Stage Renal Disease Patients? The CONvective TRAnsport STudy
por: den Hoedt, Claire H., et al.
Publicado: (2013)

Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease
por: Gevers, Tom JG, et al.
Publicado: (2012)

The When, What & How of Measuring Vitamin D Metabolism in Clinical Medicine
por: Dirks, Niek F., et al.
Publicado: (2018)

Relation between Red Cell Distribution Width and Fibroblast Growth Factor 23 Cleaving in Patients with Chronic Kidney Disease and Heart Failure
por: van Breda, Fenna, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_757u6ipebab166ur18c1p5lt0s